Expression of HBX, an oncoprotein of hepatitis B virus, blocks reoviral oncolysis of hepatocellular carcinoma cells

Cancer Gene Therapy

Volumn 16, Issue 5, 2009, Pages 453-461

  Park, E H ^a   Koh, S S ^b   Srisuttee, R ^a   Cho, I R ^a   Min, H J ^a   Jhun, B H ^a   Lee, Y S ^b   Jang, K L ^a   Kim, C H ^c   Johnston, R N ^d   Chung, Y H ^a  

^a Pusan National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Hepatitis B virus X (HBX) protein; Oncolysis; Reovirus; Type I IFN

Indexed keywords

BETA INTERFERON; DEATH RECEPTOR 5; GAMMA INTERFERON; HEPATITIS B VIRUS X PROTEIN; ONCOPROTEIN; PROTEIN KINASE R; RAS PROTEIN; SMALL INTERFERING RNA; STAT1 PROTEIN; VIRUS VECTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HEPATITIS B VIRUS; INTERFERON PRODUCTION; LIVER CELL CARCINOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY SEQUENCE; REOVIRUS; VIRUS INFECTION; VIRUS RESISTANCE;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; EIF-2 KINASE; GENE EXPRESSION REGULATION; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MICE; RAS PROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; REOVIRIDAE; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANS-ACTIVATORS;

HEPATITIS B VIRUS; ORTHOREOVIRUS;

EID: 65049086331     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.95     Document Type: Article

References (55)

1. Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004; 101: 11099-11104.
2. Kim M, Chung YH, Johnston RN. Reovirus and tumor oncolysis. J Microbiol 2001; 45: 187-192.
3. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963; 77: 29-37.
4. Nibert ML, Schiff LA, Fields BN. Mammalian reoviruses contain a myristoylated structural protein. J Virol 1991; 65: 1960-1967.
5. Duncan MR, Stanish SM, Cox DC. Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 1978; 28: 444-449.
6. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977; 54: 307-315.
7. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998; 17: 3351-3362.
8. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003; 63: 348-353.
9. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332-1334.
10. Norman KL, Lee PW. Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today 2005; 10: 847-855.
11. Yang WQ, Lun X, Palmer CA, Wilcox ME, Muzik H, Shi ZQ et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 2004; 10: 8561-8576.
12. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83(Part 3): 491-502.
13. Russel FG, Masereeuw R, van Aubel RA. Molecular aspects of renal anionic drug transport. Annu Rev Physiol 2002; 64: 563-594.
14. Ikeda Y, Nishimura G, Yanoma S, Kubota A, Furukawa M, Tsukuda M. Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris Nasus Larynx 2004; 31: 407-412.
15. Janssen HL, Higuchi H, Abdulkarim A, Gores GJ. Hepatitis B virus enhances tumor necrosis factor-related apoptosisinducing ligand (TRAIL) cytotoxicity by increasing TRAILR1/death receptor 4 expression. J Hepatol 2003; 39: 414-420.
16. Clarke P, Meintzer SM, Spalding AC, Johnson GL, Tyler KL. Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene 2001; 20: 6910-6919.
17. Tiollais P, Charnay P, Vyas GN. Biology of hepatitis B virus. Science 1981; 213: 406-411.
18. Maguire HF, Hoeffler JP, Siddiqui A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 1991; 252: 842-844.
19. Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA 1994; 91: 10350-10354.
20. Becker SA, Lee TH, Bute! JS, Slagle BL. Hepatitis B virus X protein interferes with cellular DNA repair. J Virol 1998; 72: 266-272.
21. Chung TW, Lee YC, Ko JH, Kim CH. Hepatitis B virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res 2003; 63: 3453-3458.
22. Waris G, Huh KW, Siddiqui A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress. Mol Cell Biol 2001; 21: 7721-7730.
23. Kekule AS, Lauer U, Weiss L, Luber B, Hofschneider PH. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 1993; 361: 742-745.
24. Benn J, Su F, Doria M, Schneider RJ. Hepatitis B virus HBx protein induces transcription factor AP-I by activation of extracellular signal-regulated and c-Jun N-terminal mitogenactivated protein kinases. J Virol 1996; 70: 4978-4985.
25. Chirillo P, Falco M, Puri PL, Artini M, Balsano C, Levrero M et al. Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway. J Virol 1996; 70: 641-646.
26. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol 2004; 78: 12725-12734.
27. Um HR, Lim WC, Chae SY, Park S, Park JH, Cho H. Raf-1 and protein kinase B regulate cell survival through the activation of NF-kappaB in hepatitis B virus X-expressing cells. Virus Res 2007; 125: 1-8.
28. Kim M, Egan C, Alain T, Urbanski SJ, Lee PW, Forsyth PA et al. Acquired resistance to reoviral oncolysis in Rastransformed fibrosarcoma cells. Oncogene 2007; 26: 41244134.
29. McDermott U, Longley DB, Galligan L, Allen W, Wilson T, Johnston PG. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res 2005; 65: 8951-8960.
30. Cho IR, Jeong S, Jhun BH, An WG, Lee B, Kwak YT et al. Activation of non-canonical NF-kappaB pathway mediated by STP-AIl, an oncoprotein of Herpesvirus saimiri. Virology 2007; 359: 37-45.
31. Ayroldi E, Zoilo O, Macchiarulo A, Di Marco B, Marchetti C, Riccardi C. Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1. Mol Cell Biol 2002; 22: 7929-7941.
32. Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 1996; 70: 612-616.
33. Klein NP, Schneider RJ. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Mol Cell Biol 1997; 17: 6427-6436.
34. Tarn C, Lee S, Hu Y, Ashendel C, Andrisani OM. Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J Biol Chem 2001; 276: 34671-34680.
35. Clarke P, Meintzer SM, Gibson S, Widmann C, Garrington TP, Johnson GL et al. Reovirus-induced apoptosis is mediated by TRAIL. J Virol 2000; 74: 8135-8139.
36. Lee YH, Yun Y. HBx protein of hepatitis B virus activates Jakl-STAT signaling. J Biol Chem 1998; 273: 25510-25515.
37. Lee YI, Kang-Park S, Do SI, Lee YI. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 2001 ; 276:16969-16977.
38. Uddin S, Yenush L, Sun XJ, Sweet ME, White MF, Platanias LC. Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3′-kinase. J Biol Chem 1995; 270: 15938-15941.
39. Uddin S, Fish EN, Sher D, Gardziola C, Colamonici OR, Kellum M et al. The IRS-pathway operates distinctively from the Stat-pathway in hematopoietic cells and transduces common and distinct signals during engagement of the insulin or interferon-alpha receptors. Blood 1997; 90: 2574-2582.
40. McKay DM, Botelho F, Ceponis PJ, Richards CD. Superantigen immune stimulation activates epithelial STAT-I and PI 3-K: PI 3-K regulation of permeability. Am J Physiol Gastrointest Liver Physiol 2000; 279: G1094-G1103.
41. Navarro A, Anand-Apte B, Tanabe Y, Feldman G, Lamer AC. A PI-3 kinase-dependent, Stat 1-independent signaling pathway regulates interferon-stimulated monocyte adhesion. J Leukoc Biol 2003; 73: 540-545.
42. Mulrooney-Cousins PM, Michalak TI. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol 2007; 13: 5682-5686.
43. Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007; 13: 74-81.
44. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci USA 1997; 94: 8744-8749.
45. Diao J, Khine AA, Sarangi F, Hsu E, Iorio C, Tibbies LA et al. X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of the SAPK/JNK pathway. J Biol Chem 2001; 276: 8328-8340.
46. Barton ES, Forrest JC, Connolly JL, Chappell JD, Liu Y, Schnell FJ et al. Junction adhesion molecule is a receptor for reovirus. Cell 2001; 104: 441-451.
47. Guglielmi KM, Kirchner E, Holm GH, Stehle T, Dermody TS. Reovirus binding determinants in junctional adhesion molecule-A. J Biol Chem 2007; 282: 17930-17940.
48. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001; 20: 2499-2513.
49. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295-303.
50. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol 1999; 11: 490496.
51. Srivastava SP, Kumar KU, Kaufman RJ. Phosphorylation of eukaryotic translation initiation factor 2 mediates apoptosis in response to activation of the double-stranded RNA-dependent protein kinase. J Biol Chem 1998; 273: 2416-2423.
52. Wek RC. eIF-2 kinases: regulators of general and gene-specific translation initiation. Trends Biochem Sci 1994; 19: 491496.
53. Stewart MJ, Blum MA, Sherry B. PKR's protective role in viral myocarditis. Virology 2003; 314: 92-100.
54. Zhang P, Samuel CE. Protein kinase PKR plays a stimulus- and virus-dependent role in apoptotic death and virus multiplication in human cells. J Virol 2007; 81: 8192-8200.
55. Chang KS, Cai Z, Zhang C, Sen GC, Williams BR, Luo G. Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. J Virol 2006; 80: 7364-7374.